Moreover, a newly developed anti‐TGF‐β/vascular endothelial growth factor (VEGF) bispecific antibody Y332D that exhibits reversing EMT activity can be combined with anti‐PD‐1 therapy to enhance the T cells infiltration and facilitate the T cells cytotoxicity in murine tumor model.252. Here, TGFB1 is linked to neoplasm.